Reuters logo
8 months ago
BRIEF-Interim results from phase 1b/2 study evaluating the combination of Merck's Keytruda and Eisai's Halaven injection presented at 2016 SABCS
December 12, 2016 / 12:19 PM / 8 months ago

BRIEF-Interim results from phase 1b/2 study evaluating the combination of Merck's Keytruda and Eisai's Halaven injection presented at 2016 SABCS

Dec 12 (Reuters) - Merck & Co Inc

* Interim results from phase 1b/2 study evaluating the combination of Merck's Keytruda (pembrolizumab) and Eisai's Halaven (eribulin mesylate) injection in metastatic triple-negative breast cancer presented at 2016 SABCS

* Merck & Co Inc - there were 10 discontinuations due to treatment-emergent adverse events and no treatment-related deaths during the study Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below